Dennis Kim

Dennis Kim, MD, PhD

My research is aiming to develop projects of: 1) biomarker discovery using genomics in leukemias and allogeneic stem cell transplantation; and 2) clinical research in chronic myeloid leukemia and graft-versus-host disease after allogeneic stem cell transplantation.

I have also been involved in multiple exome sequencing projects in acute myleoid leukemia (AML) with normal karyotype and secondary AML progressed from antecedent hematologic malignancies, as well as chronic myeloid leukemia (CML). My future direction of genomic research is to integrate multi-omics platforms to investigate leukemia genomes, thus dissecting clonal structures in a refined way.

Not only in translational research, but also in the clinical research field, I have shown significant progress in three ways: 1) clinical database registry; 2) retrospective studies using the database; and 3) generation of prospective clinical trials in CML and in graft-versus-host disease (GVHD) and other post-transplant complications after allogeneic stem cell transplantation.  First of all, I developed a clinical database of allogeneic transplant patients (especially for GVHD and post-transplant complications) and CML patients (especially for treatment outcomes after tyrosine kinase inhibitor therapy). Secondly, I have participated in multiple ongoing clinical retrospective studies generated from the registry database. Thirdly, I am involved in  multiple clinical trials. Currently, I am the principal investigator of a pivotal Canadian tyrosine kinase inhibitor (TKI) discontinuation clinical trial and am also a chair of the correlative part of this trial, entitled "Treatment-free Remission Accomplished with Dasatinib (TRAD)". This is the first Canadian TKI discontinutation trial for the management of CML.
Eur Respir J. 2018 Mar 15;:
Hirama T, Brode SK, Beswick J, Law AD, Lam W, Michelis FV, Thyagu S, Viswabandya A, Lipton JH, Messner HA, Kim DDH, Marras TK
Ann Hematol. 2018 Mar 02;:
Park S, Choi H, Kim HJ, Ahn JS, Kim HJ, Kim SH, Mun YC, Jung CW, Kim DDH
Oncotarget. 2018 Jan 12;9(4):4961-4968
Ahn JS, Kim HJ, Kim YK, Lee SS, Ahn SY, Jung SH, Yang DH, Lee JJ, Park HJ, Lee JY, Choi SH, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Lee YJ, Won JH, Kim SH, Zhang Z, Kim T, Kim DDH
Nat Med. 2018 Feb 12;:
Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R,...
Tissue Cell. 2017 Dec;49(6):680-690
Han KH, Kim AK, Kim MH, Kim DH, Go HN, Kang D, Chang JW, Choi SW, Kang KS, Kim DI
Haematologica. 2017 Nov;102(11):e434-e437
Kim HS, Oh SH, Kim JH, Kim JY, Kim DH, Lee SJ, Choi SU, Park KM, Ryoo ZY, Park TS, Lee S
Leukemia. 2017 Sep;31(9):1992-1995
Ha JS, Do YR, Ki CS, Lee C, Kim DH, Lee W, Ryoo NH, Jeon DS
Antivir Ther. 2017 Mar 31;:
Lam W, Al-Shaibani Z, Kumar D, Viswabandya A, Thyagu S, Michelis FV, Kim DD, Lipton JH, Messner HA, Deotare U
J Hum Genet. 2016 Oct;61(10):885-889
Jin DH, Kim S, Kim DH, Park J
Int J Cancer. 2017 Jan 01;140(1):86-94
Park C, Kim JI, Hong SN, Jung HM, Kim TJ, Lee S, Kim SJ, Kim HC, Kim DH, Cho B, Park JH, Sung J, Lee DS, Kang M, Son HJ, Kim YH